Due to the involvement of TDP-43 dysfunction in other diseases such as Alzheimer’s disease [106, 108–110, 137], LATE [15, 106], and inclusion body myositis [132, 133], the utility of these cryptic peptide biomarkers could extend beyond ALS and FTD. This evidence concerns the gene TARDBP and frontotemporal dementia.